CKCharline Kieffer

Charline Kieffer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Charline Kieffer has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    C(sp)-C(sp2) Bond Formation from Triflates via a Copper-Free Sonogashira Cross-Coupling

    by Thomas Lemaitre, Marie Cornu, Anne Sophie Voisin-Chiret, Thomas Cailly, Charline Kieffer

    A rapid and copper-free Sonogashira cross-coupling enabling the direct use of aryl triflates as electrophiles is reported. The palladium-catalyzed protocol operates under simple and robust conditions, overcoming common limitations associated with triflate substrates. Broad scope is demonstrated across electron-rich, electron-neutral, moderately electron-deficient, and heteroaryl triflates, as well as diverse aromatic and aliphatic terminal alkynes. Extension to vinyl triflates further highlights the versatility of the method, offering a practical alternative to the use of corresponding aryl and vinyl halides for C(sp)-C(sp2) bond formation.

  • Open Access

    Integrative in silico and experimental identification of non-covalent UBE2N inhibitors enhancing PARP inhibitor sensitivity

    by Côme Ghadi, Shafi Ullah Khan, Léonie Ibazizene, Florian Schwalen, Charline Kieffer, Peggy Suzanne, Julie Jaouen, Hassiba Bouafia, Xavier Thuru, Marie Cornu, et al.

  • Open Access

    ID Card of Mcl-1 PROTAC degrader: From in silico design to biological validation in chemoresistant ovarian cancer

    by Marie Cornu, Jocelyn Pezeril, Nicolas Guedeney, Hippolyte Paysant, Thomas Lemaitre, Florian Schwalen, Romane Florent, Julie N'GUyen, Sophie Corvaisier, Marc Since, et al.

  • Pharmacochimie antiprotozoaire en séries quinazoline et quinoléine : synthèse, évaluation biologique et recherchedu mécanisme d'action.

    by Charline Kieffer

    Le paludisme et la leishmaniose sont les deux plus importantes infections parasitaires au monde, en termes de mortalité. La recherche de nouvelles molécules actives contre les protozoaires responsables de ces « maladies tropicales négligées », Plasmodium sp et Leishmania sp, est un enjeu majeur de santé publique. Après une première partie dressant un état des lieux des connaissances disponibles en matière de chimiothérapie antiplasmodiale, une seconde partie s’est intéressée à l’étude des propriétés anti-infectieuses du noyau 2-trichlorométhyl-quinazoline, en introduisant en position 4 des motifs alcynyles par couplage de Sonogashira, optimisés par LC/MS. Une troisième partie a porté sur la pharmacomodulation en positions 2 et 4 du même noyau, notamment par réactions de SNAr. Une quatrième partie a consisté à rechercher le mécanisme d'action des meilleures quinazolines antiplasmodiales, via une approche de chromatographie d'affinité sur inhibiteur immobilisé. La fonctionnalisation multi-étapes des molécules les plus puissantes, par un bras espaceur, a été suivie de leur ancrage sur divers supports solides, pour constituer des matrices biocompatibles spécifiques. L’une d’entre-elles a permis la mise en évidence de 2 cibles plasmodiales protéiques originales : la GTPase Pfrab6 et la pyruvate-kinase PfpyrK1. Enfin, une cinquième partie relate la pharmacomodulation antileishmanienne du noyau 8-nitroquinoléin-2(1H)-one. Les travaux se sont intéressés à l'étude de la substitution de la position 4 de ce noyau par des réactions de SNAr, ainsi que des réactions de couplages pallado-catalysés optimisées à l’aide de la technologie micro-ondes.

  • UBE2N: Hope on the Cancer Front, How to Inhibit This Promising Target Prospect?

    by Florian Schwalen, Côme Ghadi, Léonie Ibazizene, Shafi Ullah Khan, Jana Sopkova-De Oliveira Santos, Louis-Bastien Weiswald, Anne Sophie Voisin-Chiret, Matthieu Meryet-Figuiere, Charline Kieffer

    UBE2N protein belongs to the UE2s family and plays a crucial role in DNA repair, making it an exciting target for the development of innovative anticancer therapies. With the aim of discovering UBE2N inhibitors (UBE2Ni), this perspective seeks to review and provide elements to guide the design of new compounds. We propose a chemoinformatic structural analysis of the protein and its areas of interaction with its different partners. While covalent UBE2Ni are the most advanced molecules in their development, noncovalent inhibitors offer significant advantages that could overcome the limitations of covalent ones, particularly in terms of selectivity. Lastly, to obtain a drug candidate, early assessment of the druggability of compounds is essential in a hit to lead process. For existing UBE2Ni, a critical challenge lies in their pharmacokinetic properties and will obviously have to be considered as early as possible to hope for an application in human therapy.


  • Towards New Anti‐Inflammatory Agents: Design, Synthesis and Evaluation of Molecules Targeting XIAP‐BIR2

    by Marc Farag, Nicolas Guedeney, Florian Schwalen, Aymeric Zadoroznyj, Amélie Barczyk, Martin Giret, Kevin Antraygues, Alice Wang, Marie Cornu, Peggy Suzanne, et al.

    The X‐chromosome‐linked inhibitor of apoptosis protein (XIAP) plays a crucial role in controlling cell survival across multiple regulated cell death pathways and coordinating a range of inflammatory signalling events. The discovery of selective inhibitors for XIAP‐BIR2, able to disrupt the direct physical interaction between XIAP and RIPK2, offer promising therapeutic options for NOD2‐mediated diseases like Crohn's disease, sarcoidosis, and Blau syndrome. The objective of this study was to design, synthesize, and evaluate small synthetic molecules with binding selectivity to XIAP‐BIR2 domain. To achieve this, we applied an interdisciplinary drug design approach and firstly we have synthesized an initial fragment library to achieve a first XIAP inhibition activity. Then using a growing strategy, larger compounds were synthesized and one of them presents a good selectivity for XIAP‐BIR2 versus XIAP‐BIR3 domain, compound 20 c. The ability of compound 20 c to block the NOD1/2 pathway was confirmed in cell models. These data show that we have synthesized molecules capable of blocking NOD1/2 signalling pathways in cellulo, and ultimately leading to new anti‐inflammatory compounds.


  • Molecular glue degraders: exciting opportunities for novel drug discovery

    by Thomas Lemaitre, Marie Cornu, Florian Schwalen, Marc Since, Charline Kieffer, Anne Sophie Voisin-Chiret

    Molecular Glue Degraders (MGDs) is a concept that refers to a class of compounds that facilitate the interaction between two proteins or molecules within a cell. These compounds act as bridge that enhances specific Protein-Protein Interactions (PPIs). Over the past decade, this technology has gained attention as a potential strategy to target proteins that were traditionally considered undruggable using small molecules. This review presents the concept of cellular homeostasis and the balance between protein synthesis and protein degradation. The concept of protein degradation is concerned with molecular glues, which form part of the broader field of Targeted Protein Degradation (TPD). Next, pharmacochemical strategies for the rational design of MGDs are detailed and illustrated by examples of Ligand-Based (LBDD), Structure-Based (SBDD) and Fragment-Based Drug Design (FBDD). Expanding the scope of what can be effectively targeted in the development of treatments for diseases that are incurable or resistant to conventional therapies offers new therapeutic options. The treatment of microbial infections and neurodegenerative diseases is a major societal challenge, and the discovery of MGDs appears to be a promising avenue. Combining different approaches to discover and exploit a variety of innovative therapeutic agents will create opportunities to treat diseases that are still incurable.


  • Open Access

    Computational Tool to Design Small Synthetic Inhibitors Selective for XIAP-BIR3 Domain

    by Marc Farag, Charline Kieffer, Nicolas Guedeney, Anne Sophie Voisin-Chiret, Jana Sopkova-De Oliveira Santos

    X-linked inhibitor of apoptosis protein (XIAP) exercises its biological function by locking up and inhibiting essential caspase-3, -7 and -9 toward apoptosis execution. It is overexpressed in multiple human cancers, and it plays an important role in cancer cells’ death skipping. Inhibition of XIAP-BIR3 domain and caspase-9 interaction was raised as a promising strategy to restore apoptosis in malignancy treatment. However, XIAP-BIR3 antagonists also inhibit cIAP1-2 BIR3 domains, leading to serious side effects. In this study, we worked on a theoretical model that allowed us to design and optimize selective synthetic XIAP-BIR3 antagonists. Firstly, we assessed various MM-PBSA strategies to predict the XIAP-BIR3 binding affinities of synthetic ligands. Molecular dynamics simulations using hydrogen mass repartition as an additional parametrization with and without entropic term computed by the interaction entropy approach produced the best correlations. These simulations were then exploited to generate 3D pharmacophores. Following an optimization with a training dataset, five features were enough to model XIAP-BIR3 synthetic ligands binding to two hydrogen bond donors, one hydrogen bond acceptor and two hydrophobic groups. The correlation between pharmacophoric features and computed MM-PBSA free energy revealed nine residues as crucial for synthetic ligand binding: Thr308, Glu314, Trp323, Leu307, Asp309, Trp310, Gly306, Gln319 and Lys297. Ultimately, and three of them seemed interesting to use to improve XIAP-BR3 versus cIAP-BIR3 selectivity: Lys297, Thr308 and Asp309.


  • PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery

    by Nicolas Guedeney, Marie Cornu, Florian Schwalen, Charline Kieffer, Anne Sophie Voisin-Chiret


  • Open Access

    Azobenzene Photoswitches in Proteolysis Targeting Chimeras: Photochemical Control Strategies and Therapeutic Benefits

    by Arvind Negi, Charline Kieffer, Anne Sophie Voisin‐Chiret

    The photoswitchable‐PROTACs have photoswitches that work as an actual ON/OFF switch for any particular bioactivity. In reported studies, the ON/OFF activity correlates with the photostationary state and quantum yield of a specific isomer under a definite wavelength of light, providing a spatiotemporal control over protein degradation (an example of photochemistry‐based precision medicine). The studies reported the role of azobenzenes as photoswitches ( ortho ‐tetramethoxybenzenes, ortho‐tetraflurobenzenes as push‐pull and push‐push) to develop light‐controlled PROTACs. This paper discussed the photophysical properties of photoswitchable‐PROTACs (such as photoisomerization, quantum yield, and thermal relaxation states) and correlated their photochemical‐based structural bioactivity relationships. The proteins studied under photoswitchable‐PROTACs are kinase proteins: BCR‐ABL fusion protein, ABL; Bromodomain proteins: BRD2, 3, 4; Immunophilins: FKBP12.